Medicine

Data from trials highlight long-term disease control and quality of life improvements UCB has announced new three-year data for BIMZELX (bimekizumab) in moderate to

Durvalumab becomes first immunotherapy recommended for LS-SCLC patients in England and Wales AstraZeneca’s Imfinzi (durvalumab) has been approved for NHS use in England and

Positive orphan drug opinion supports SOM3355’s potential as first-line treatment in Europe SOM Biotech has received a positive opinion from the European Medicines Agency’s

Arcinova has appointed Dr Christian Dowdeswell as Managing Director Arcinova, a Quotient Sciences company and UK-based contract research development and manufacturing organisation (CRDMO), has announced the

New phase 4 results show sustained symptom relief and improved patient outcomes Lundbeck has presented new clinical data on eptinezumab at the 2025 International

Merck presents phase 3 STRIDE-13 trial results at ESCMID conference in Lisbon Merck has announced positive phase 3 results for Capvaxive, its 21-valent pneumococcal

Abcuro has appointed George Eldridge as chief financial officer Abcuro Inc, a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer

Early data reveals strong response rates in ovarian cancer cohort PMV Pharma has announced encouraging interim results from the phase 2 portion of its

First patient enrolled in AZURE-2 study comparing brelovitug to Hepcludex Bluejay Therapeutics has enrolled the first patient in AZURE-2, a global phase 3 clinical

New partnership aims to fast-track mRNA therapies from lab to clinic Quotient Sciences and CPI have signed a memorandum of understanding to form a

Novel orexin receptor agonist shows potential to improve wakefulness Eisai has presented new clinical data for its investigational orexin 2 receptor agonist E2086 at

Topical TRPV1 antagonist shows promise in heat-induced neuropathic pain lzeCure Pharma has presented new clinical data on its lead pain candidate ACD440 at the

Survey reveals lack of awareness need for greater clarity

Trial explores regenerative macrophage therapy for liver disease Resolution Therapeutics has announced that the first patient has been dosed and safety cleared in its

Blended solutions gain momentum and reveal untapped potential

Collaboration offers end-to-end support from donor sourcing to manufacturing eXmoor Pharma and Anthony Nolan: Cell Therapy & Laboratory Services (CT&LS) have announced a strategic

Deal covers biosimilars for gastroenterology, neurology and dermatology Polpharma Biologics has signed licensing agreements with MS Pharma for the commercialisation of three proposed biosimilars

MHRA grants conditional authorisation for treatment targeting mantle cell lymphoma Eli Lilly and Company has received conditional marketing authorisation from the MHRA for pirtobrutinib

New subcutaneous autoinjector offers at-home treatment option for patients Eisai and Biogen have announced FDA approval of LEQEMBI IQLIK (lecanemab-irmb) for maintenance dosing in

The US Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application from Coya Therapeutics for COYA 302, enabling the company

Swedish biotech company Akiram Therapeutics has announced significant progress in its first clinical trial of AKIR001, a radiopharmaceutical intended to treat aggressive solid tumours.

HUTCHMED has announced that Weiguo Su, CEO of the company, will take a leave of absence from his duties due to health reasons. As

Encare’s ERAS Interactive Audit System (EIAS) has earned qualification on the Mayo Clinic Platform_Solutions Studio – a distinction rarely awarded to European solutions. The

Eli Lilly and Company has announced that Anne White, executive vice president and president of Lilly Neuroscience, will retire at the end of 2025

Novartis has reported that its experimental drug ianalumab met the primary goal in a phase 3 trial for primary immune thrombocytopenia (ITP), a rare

Top-rated pharmacies in northern Virginia for personalised fertility care Finding the right pharmacy to support your fertility journey is essential. What are the top-rated

Friends of Cancer Research has announced a new collaboration with global clinical research organisation, MMS, to develop decision frameworks that will help interpret interim

ANGLE has announced a collaboration with Myriad Genetics to assess whether circulating tumour cell (CTC) DNA harvested from blood samples using ANGLE’s Parsortix system

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to izalontamab brengitecan (iza-bren), an investigational drug developed by SystImmune and

Upperton Pharma Solutions has been awarded funding under the first VaxHub Sustainable Platform Funding Call to support the development of oral formulations for adenovirus-vectored

Project aims to improve global immunisation through needle-free delivery Upperton Pharma Solutions has secured funding from the first VaxHub Sustainable Platform Funding Call to

Merck’s therapy becomes first authorised option for aggressive soft tissue tumours Merck has announced that the European Commission has granted marketing authorisation for Ogsiveo

New treatment option now available across all UK nations Patients in Scotland with relapsed or refractory mantle cell lymphoma (MCL) after one line of

New phase of development targets chronic pain and fibromyalgia Sever Pharma Solutions has deepened its partnership with Silo Pharma to advance a novel ketamine-based

Lilly’s study finds tirzepatide delivers broader health improvements Eli Lilly has announced positive topline results from its phase 3 SURPASS-CVOT trial, comparing Mounjaro (tirzepatide)

Company shifts focus to phase 3 VE303 trial in recurrent C. difficile infection Vedanta Biosciences has announced that VE202 failed to meet the primary

Promising results support global submissions and priority review by US FDA Genmab has announced that its phase 3 EPCORE FL-1 trial met both primary

Teva’s CGRP therapy becomes first approved option for children and adolescent Teva Pharmaceuticals has received US FDA approval for AJOVY (fremanezumab-vfrm) as a preventive

Nationwide competition to pilot new models of obesity support Eli Lilly and Company and the UK Government have announced a joint programme to develop

Pirtobrutinib meets primary endpoint in CLL/SLL study Eli Lilly and Company has announced positive topline results from its phase 3 BRUIN CLL-314 trial of

Celltrion’s biosimilar now fully aligned with ACTEMRA IV indications in US Celltrion has received US Food and Drug Administration approval for an expanded indication

New first-line option for patients with pMMR and dMMR tumours in England NICE has recommended KEYTRUDA (pembrolizumab) with carboplatin and paclitaxel chemotherapy as a

FDA validation and AI-designed therapies mark major shift in treatment strategy Porosome Therapeutics has announced major advances in Alzheimer’s disease research, including FDA validation

New oral GLP-1 agonist aims to reshape chronic weight management Nxera Pharma has launched a broad proprietary pipeline focused on next-generation therapies for obesity

Dydrogesterone-only tablet returns after 17-year absence to support personalised care Gedeon Richter UK has launched Nalvee (10mg dydrogesterone) in the UK, marking the return

New drug delivery system could transform treatment for chronic conditions Scientists at the University of Bath have developed a new technology that could allow

MB310 study investigates safety and efficacy of precision microbiome therapy Microbiotica has completed patient recruitment for its phase 1b trial, COMPOSER-1, evaluating MB310 in

US$30.9 million strategic equity deal strengthens oncology platform Everest Medicines has announced a strategic equity investment of US$30.9 million in I-Mab, acquiring 15,846,154 newly

Spikevax authorised to target LP.8.1 variant ahead of 2025-2026 season Moderna has received marketing authorisation from the European Commission for its updated COVID-19 vaccine,

Four-year treatment slows cognitive decline with consistent safety profile Eisai has presented new clinical data showing that patients with early Alzheimer’s disease continue to

Imfinzi and Imjudo combination recommended as first-line treatment AstraZeneca has received a positive recommendation from NICE for the use of Imfinzi (durvalumab) with Imjudo

Alfasigma to seek regulatory approval following OLINGUITO study success Alfasigma has announced positive topline results from its OLINGUITO phase 3 trial evaluating filgotinib in

Still time to enter – but not much! Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas! Introducing the Clinical Research

CLEAR-DE study to assess topical therapy for non-proliferative diabetic retinopathy Exonate has announced plans to initiate a phase 2b clinical trial of its lead

Veranova has appointed Elizabeth Rebeil as VP of Supply Chain Excellence Veranova has appointed Elizabeth Rebeil as Global Vice President of Supply Chain and Operational Excellence. Bringing over 20 years

CHMP recommends authorization for LP.8.1-targeting vaccine ahead of 2025-2026 season Moderna has received a positive opinion from the European Medicines Agency’s Committee for Medicinal

Collaboration aims to advance next-generation therapeutics and vaccines Kling Bio has announced a new collaboration and licence option agreement with Sanofi to accelerate the

Akari Therapeutics has reaffirmed its commitment to advancing research on PH1, a novel spliceosome modulator payload used in its antibody drug conjugates (ADCs), which

Irish biotech’s germ-free egg platform could help close global shortfall Irish biotech Ovagen has announced a major advance in vaccine manufacturing, with new data

First patient dosed in phase 1b/2a study of procizumab 4TEEN4 Pharmaceuticals has dosed the first patient in a phase 1b/2a trial of procizumab, a

Enter this year’s thrilling competition! Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas! Introducing the Clinical Research Associate (CRA) category.

GlueSEEKER enables rational design of targeted protein degraders PhoreMost has published new data validating its GlueSEEKER platform, a high-throughput technology designed to accelerate molecular

EC grants conditional marketing authorisation to Merck and SpringWorks Therapeutics The European Commission has approved EZMEKLY (mirdametinib) for treatment of symptomatic, inoperable plexiform neurofibromas

Clinical results from phase 2 study highlight analgesic effects in neuropathic pain patients AlzeCure Pharma will present new clinical data for its drug candidate

Funding to accelerate development of AI-driven tumour profiling tool OneMap One Biosciences has secured €15 million in Series A financing to expand its AI-powered

First patient dosed in BUOY-1 study targeting MDD with or without anxious distress Seaport Therapeutics has dosed the first patient in its phase 2b

Digital operating rooms and histotripsy therapy combine to improve outcomes Proximie has announced a new partnership with HistoSonics to support the rollout of the

Healthinote rollout aims to improve early detection and patient self-management North East and North Cumbria NHS has begun a year-long rollout of the Healthinote

Sebetralstat offers injection-free relief for patients aged 12 and over The MHRA has approved sebetralstat (Ekterly) as the first oral, on-demand treatment for hereditary

Vertex’s once-daily triple therapy approved for eligible patients aged six and over Vertex Pharmaceuticals has announced a broad reimbursement agreement with NHS England for

Researchers at Imperial College London have discovered that an unusual DNA structure could be key to reversing chemotherapy resistance in ovarian cancer, one of

New treatment targets BRAFV600E-mutant mCRC after prior therapy Pierre Fabre Laboratories have received marketing authorisation in China for BRAFTOVI (encorafenib) in combination with cetuximab

OVX836 shown to be safe and effective alongside seasonal Fluarix Tetra Osivax has released phase 2a trial data confirming that its broad-spectrum flu vaccine

New regulations aim to simplify processes and strengthen patient safety The Government is set to amend UK medical devices regulations by adopting EU Common

Funding to support lead candidate targeting FAP and pipeline expansion Actithera has secured $75.5 million in an oversubscribed Series A round to support the

BX004 achieves 500-fold bacterial reduction with no resistance in phase 1b/2a study BiomX has published promising phase 1b/2a trial results in Nature Communications, demonstrating

Enter the 2025 PharmaTimes Clinical Researcher of the Year – The Americas Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas!

New trial to test VMX-C001’s effectiveness in restoring coagulation in FXa DOAC patients Biotech company VarmX has received clearance from the US FDA to

SMC approval provides option for postmenopausal women at risk of fractures The Scottish Medicines Consortium has recommended Eladynos (abaloparatide) for treating osteoporosis in postmenopausal

PulseSight begins phase 1 safety study of gene therapy for geographic atrophy PulseSight Therapeutics has announced that the first patient has been dosed in

CSL Behring marks new era in treatment with milestone reimbursement model The first haemophilia B patient in Germany has been treated with the one-time

Clinigen has appointed Paul Carter as Non-Executive Chair of its Board Clinigen, the global pharmaceutical services Group, has appointed seasoned biopharma executive Paul Carter as Non-Executive Chair

Enhanced Genomics appoints Dr Dietrich Stephan as Chair of the Board Enhanced Genomics has appointed Dr Dietrich Stephan as Chair of the Board of Directors. In this role,

Pneumagen’s intranasal antiviral demonstrates reduced infection Pneumagen has announced the publication of phase 2 data showing its antiviral therapy, Neumifil, significantly reduced influenza infection

Data shows mRNA-1010 could better protect adults aged 50 and above Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010,

Closed Loop Medicine has appointed Kate Woolland as CEO Closed Loop Medicine (CLM) has appointed Kate Woolland as Chief Executive Officer. Previously serving as Chief Operating Officer,

New data show strong efficacy of CD388 in phase 2b trial Cidara Therapeutics and hVIVO have announced encouraging topline results from a global phase

Positive trial results offer hope for those with ultra-rare epileptic disorder UCB has announced that its phase 3 trial evaluating fenfluramine in CDKL5 deficiency

Transforming community prescribing through innovation As the NHS places an increasing focus on strengthening primary care and enhancing community-based prescribing, it is up to

Why supporting representative trial participation matters

This year’s event took place on 11 to 12 June at Manchester Central This year’s NHS ConfedExpo took place on 11 to 12 June

VectorY Therapeutics has appointed Jessica Atkinson as Chief Business Officer VectorY Therapeutics has appointed Jessica Atkinson as Chief Business Officer. In this newly created role, she will support the CEO

The programme was unveiled at this year’s NHS ConfedExpo in Manchester PMGroup Worldwide and Visions4Health have launched the Excellence in Healthcare Partnerships (EHP) Awards

Enter this year’s famous competition Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas! Introducing the Novice Clinical Research Associate (CRA)

Biocartis has appointed Ben Svarczkopf as Senior Vice President of Global Marketing Biocartis Group of Companies (Biocartis) has announced the appointment of Ben Svarczkopf

The pilot will see GP practices look at patient records to identify those most at risk The NHS has announced the launch of a

iOnctura has appointed Steven Sciuto as Chief Financial Officer iOnctura has announced the appointment Steven Sciuto as its new Chief Financial Officer. Sciuto holds

Kallikor has appointed Chris Brett as Chief Technology and Product Officer Kallikor has announced the appointment of Chris Brett as its new Chief Technology

Signadori is advancing a platform designed to overcome the challenges of treating solid cancers eXmoor Pharma and Signadori Bio have entered into a partnership

Aravax has appointed Louise Peacock as Chief Regulatory and Quality Officer Aravax has announced the appointment of Louise Peacock as its new Chief Regulatory

The candidate is being evaluated as both a monotherapy and in combination pembrolizumab Teva Pharmaceutical Industries and Shanghai Fosun Pharmaceutical (Fosun Pharma) have announced

Approximately 59,000 LG-IR-NMIBC patients experience recurrent disease every year in the US The US Food and Drug Administration (FDA) has approved UroGen Pharma’s Zusduri

Collaboration aims to improve rapid detection and personalised treatments EDX Medical Group has entered into an agreement with Spire Healthcare Group to advance diagnostic

Results suggest bispecific antibody combination could improve outcomes A new investigational treatment has shown strong and lasting responses in multiple myeloma patients with extramedullary

Tozaro has appointed Dr Jason Slingsby as Chief Executive Officer Tozaro has announced the appointment of Dr Jason Slingsby as Chief Executive Officer. Jason will lead the company’s long-term strategy,

Rheumatology studies show promising results for Sjogren’s disease Argenx has presented positive phase 2 results for efgartigimod in myositis and Sjogren’s disease at EULAR

EMHA calls for its inclusion in EU neurological health strategy The European Migraine and Headache Alliance (EMHA) has urged EU policymakers to include migraine

Biotech firm shares phase 2 findings on novel osteoarthritis treatmen Levicept has presented new data from its phase 2 trial of LEVI-04 at the

Personalisation is the future of cancer care

Three-year data highlights inflammation control in psoriatic arthritis UCB has announced new three-year data from phase 3 trials and their open-label extensions investigating BIMZELX

Clinigen has appointed Nihad Hasagic as SVP for CLS Clinigen has appointed Nihad Hasagic as Senior Vice President for Clinigen Lifecycle Services (SVP CLS). CLS plays a key role in

Biotech firm to collaborate with NHS on early detection study Tagomics has been awarded £860k in funding from Innovate UK’s Biomedical Catalyst programme to

Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas! Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas!

Tozaro has announced the appointment of Dr Jason Slingsby as Chief Executive Officer. Jason will lead the company’s long-term strategy, including commercialisation of its Smart Polymer technology

Richard Condon, CEO Aspire Pharma, discusses successful leadership

New funding supports development of diagnostic platform Birmingham spin-out Linear Diagnostics has secured £1m funding to advance a rapid test for sexually transmitted infections

Therapy indicated for children aged 3 to 14 at treatment initiation Santen has announced that the European Commission has granted market authorisation for Ryjunea,

Last month, I had the privilege of hosting a webinar for the National Institute for Health and Care Research (NIHR) on ‘Strategies for Growing

Treatment provides option for children with growth failure The National Institute for Health and Care Excellence (NICE) has recommended Sogroya (somapacitan injection) for children

Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas! Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas!

Updated guidance from NICE expands eligibility for dapagliflozin us The National Institute for Health and Care Excellence (NICE) has published updated guidance recommending Forxiga

New guidance expands treatment options for eligible patients The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending mirikizumab

Worldwide Clinical Trials has appointed Stephen Rayda as Chief Digital and Information Officer Worldwide Clinical Trials has appointed Stephen Rayda as its first Chief

The alliance combines Lumanity’s commercial and development strategy capabilities with PICI’s translational research expertise Lumanity and the Parker Institute for Cancer Immunotherapy (PICI) have

Global biopharma Eli Lilly will acquire SiteOne Therapeutics, a biotech dedicated to the development of non-opioid medicines to treat pain and other neuronal hyperexcitability

TQ Therapeutics (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics, through a share purchase agreement. Juno GmbH was previously owned

Company secures regulatory approvals for commercial rollout in UK and US With over 55 million people worldwide living with dementia, Oxford Brain Diagnostics (OBD)

First non-immunosuppressive dual-action therapy approved for eligible patients The National Institute for Health and Care Excellence (NICE) has recommended FILSPARI (sparsentan) for use in

Kelso Pharma has appointed Bee Koen Low as Chief Operating Officer Kelso Pharma has announced the appointment of Bee Koen Low as its first

Strategic collaboration aims to improve early diagnosis Sonrai Analytics and AOA Dx have announced a partnership to accelerate the development of AOA’s multi-omic liquid

The Board of the Medicines and Healthcare products Regulatory Agency (MHRA) has met in Scotland for the first time, marking a significant step in

The drug was recently approved in the US for familial chylomicronaemia syndrome Ionis Pharmaceuticals has shared positive top-line results from a late-stage study of

Veranova has appointed Elizabeth Rebeil as Global Vice President of Supply Chain and Operational Excellence Veranova has announced the appointment of Elizabeth Rebeil as

Brekiya is now the first DHE auto-injector to be approved by the regulator The US Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals’

Biotech spin-off targets fibrosis, neoplasm and neovascularization Massalia Therapeutics, a biotechnology spin-off from the C2VN Institute, has officially launched with a mission to develop

Regulator confirms safety and efficacy of new treatment option for patient The Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) for

Aspire-FTD study aims to stop disease progression with one-time treatment AviadoBio has launched its phase 1/2 Aspire-FTD trial in the UK, assessing AVB-101, a

Asgard Therapeutics has appointed Shane Olwill as Chief Development Officer Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy,

FDA recognises KER-0193 as a potential therapy for rare paediatric disease Kaerus Bioscience has received orphan drug and rare paediatric drug designations from the

Trial progresses towards topline data expected later in the year Herantis Pharma has dosed the first patients in the final cohort of its phase

Screening begins for study evaluating LTI-03 in idiopathic pulmonary fibrosi Rein Therapeutics has begun screening and recruiting patients for its renew phase 2 trial,

Ellab has appointed Gergely Sved as its new Chief Executive Officer Ellab, the provider of validation, monitoring and calibration services and solutions, has appointed Gergely Sved as its

Fiona Smith-Laittan has been appointed Chair of Cambridge Global Health Partnerships Fiona Smith-Laittan, Vice President of Global Health Strategy and Partnerships at GlaxoSmithKline (GSK),

Private equity firm Apiary Capital backs rapid growth of performance-i Apiary Capital has completed its investment in performance-io (PIO), a leading life sciences performance

Demonstrate your skill and prowess by entering this year’s awards! For 2025, The 2025 PharmaTimes Clinical Researcher of the Year – The Americas Awards

Teprotumumab approved as first targeted treatment for thyroid eye disease The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for

Study explores whether PI3Kδ targeting could combat resistance iOnctura has begun a randomized phase 1/2 study investigating its lead asset, roginolisib, in combination with

UCB’s developmental treatment may be eligible for patient access UCB has announced that its developmental treatment DoxTM, a combination of doxecitine and doxribtimine, has

Company seeks approval for new schedules to improve patient convenience Janssen-Cilag International NV, a Johnson & Johnson company, has submitted an application to the

New initiative aims to accelerate diagnosis and ease NHS pressures Chiesi UK and Ireland and Wirral Primary Care Collaborative (WPCC) have launched COMET, a

Cambridge firm in-licenses two oncology programmes Mosaic Therapeutics a UK-based oncology company has announced it has in-licensed two clinical-stage oncology programmes from Astex Pharmaceuticals.

Approval marks milestone for AI use in frontline care NICE has endorsed DERM, an autonomous AI medical device developed by Skin Analytics, for detecting

Application seeks reduced infusion frequency to support patient flexibility Eisai Europe and Biogen Idec have announced the validation of a Marketing Authorisation Variation by

Study paves the way for personalised therapies for osteoarthritis sufferer Groundbreaking research has identified over 900 genetic links to osteoarthritis, including 500 previously undiscovered,

New therapy offers hope for patients with limited option Regeneron Pharmaceuticals has announced that the European Commission has conditionally approved Lynozyfic (linvoseltamab) for adults

Today’s leaders are building a stronger, more inclusive future for the industry

CHMP recommendation brings new hope for patients Takeda has announced a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending

Aspire Pharma has appointed Katharina Pink as Chief Commercial Officer Aspire Pharma has announced the appointment of Katharina Pink as Chief Commercial Officer and

VYVGART could be the first CIDP drug with a novel mechanism in 30 years Argenx has announced that the Committee for Medicinal Products for

Kymera Therapeutics has appointed Noah Goodman as Chief Business Officer Clinical-stage biopharma Kymera Therapeutics has announced the appointment Noah Goodman as its new Chief

The university has been awarded a £1m grant from LifeArc and Muscular Dystrophy UK Researchers from University College London (UCL) are aiming to develop

MHRA authorises drug for adults with rare heart muscle damage The Medicines and Healthcare products Regulatory Agency (MHRA) has given the green light to

Mosaic Therapeutics a UK-based oncology company has announced it has in-licensed two clinical-stage oncology programmes from Astex Pharmaceuticals. The agreement transforms Mosaic from a

Where to purchase reliable pharmacy automation systems Technological advancements propel the pharmaceutical industry into the future. Better equipment makes it easier to fulfill your

Terumo BCT has appointed Patrick Daly as Chief Business Officer Terumo Blood and Cell Technologies (Terumo BCT) has announced the appointment of Patrick Daly

It is hoped that the MAGIC-I study will support earlier diagnosis and personalised treatment A five-year clinical study aiming to optimise childhood cancer care

ABPI has appointed Russell Abberley as President-elect The Association of the British Pharmaceutical Industry (ABPI) has appointed Russell Abberley, Vice President and General Manager

The SHIELD-Utah study compared Novavax’s vaccine to the Pfizer/BioNTech mRNA 2024-2025 vaccine Novavax has shared positive preliminary results from a real-world study of its

Oncodesign Services has appointed Aidan Synnott as CEO Oncodesign Services has announced the appointment of Aidan Synnott as its new Chief Executive Officer (CEO).

More than 37 million adults in the US are affected by migraine The US Food and Drug Administration (FDA) has approved Click Therapeutics’ CT-132

New real-world data reinforce treatment benefit Real-world data from the University of Catania, Italy, suggest that Pepaxti, a treatment for relapsed, refractory multiple myeloma

European Commission grants authorisation for Eisai and Biogen therapy The European Commission has granted marketing authorisation for Leqembi (lecanemab), making it the first therapy

Studies show improved bone mineral density and healthcare cost reductions New data from multiple countries confirm the effectiveness of romosozumab, the dual-acting osteoporosis treatment

Long-term survival projections suggest improved outcomes for patients New data from Janssen-Cilag International NV suggest that subcutaneous DARZALEX (daratumumab) quadruplet therapy could offer a

Birmingham researchers to make MGUS monitoring more efficient Birmingham researchers have received £230k from Cancer Research Horizons to develop a prototype test for monitoring

Major update aims to accelerate research and strengthen patient safety New UK clinical trials regulations have been signed into law, with a 12-month rollout

The model could lead to more targeted treatments for the disease Cancer Research scientists have developed a new cell-based model of lung squamous cell

Johnson & Johnson’s Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration Balversa (erdafitinib) has been recommended for

AI-powered SkyMind is designed to improve efficiency, compliance and decision-making SkyCell has partnered with Microsoft to launch SkyMind, an artificial intelligence (AI)-powered solution designed

An estimated 7.5 million people will be invited to receive the booster The NHS has started delivering its spring COVID-19 vaccine booster to vulnerable

Angelini Ventures has appointed Regina Hodits as managing director Angelini Ventures has announced the appointment of Regina Hodits as its new managing director. Hodits

Approximately 55,100 new cases of prostate cancer are diagnosed every year in the UK The Medicines and Healthcare products Regulatory Agency (MHRA) has approved

The Scottish Medicines Consortium (SMC) has approved bimekizumab for adults with active moderate to severe hidradenitis suppurativa (HS) who have not responded to conventional

Research targets lysosomal function restoration for neurodegeneration Endlyz Therapeutics has launched from stealth, unveiling its pipeline of small molecule modulators designed to restore lysosomal

Women are shaping new dimensions throughout industry Having women in the pharmaceutical industry is crucial because it brings diverse perspectives and experiences. It also

Women in healthcare and pharma – progress, challenges and outcomes

Collaboration introduces automation to enhance efficiency Elekta has announced a partnership with Azra AI to improve cancer registry workflows using AI-powered automation. Combining Elekta’s

Approval extends ustekinumab’s use to younger patients The European Commission (EC) has approved ustekinumab for the treatment of moderately to severely active Crohn’s disease

Advancing care for stage 3 or 4 Hodgkin lymphoma patients The National Institute for Health and Care Excellence (NICE) has recommended brentuximab vedotin combined

GMP certification enables 4basebio to supply DNA for clinical trials 4basebio PLC has been granted Good Manufacturing Practice (GMP) certification by the UK’s Medicines

Collaboration expands AI-based risk profiling tools Diagnexia has announced a partnership with Stratipath AB to bring Stratipath Breast, an AI-based prognostic risk profiling tool,

Are biotechs underestimating regulatory groundwork

The vital link between human and animal well-being The next pandemic will require crucial collaboration between veterinarians and medical professionals. Are we ready? Many

When Integrated DNA Technologies (IDT) launched its Collab Network in February 2023, the goal was to speed up the pace of genomics innovation through

Janssen drug combination extends life expectancy during trial Janssen-Cilag International NV has announced results from the phase 3 MARIPOSA study, demonstrating a significant overall

New therapy developed to repair GJB2 R75W mutation Scientists from Juntendo University and The University of Tokyo have created an adeno-associated virus (AAV)-based genome

NOUS-209 shows potential to intercept cancer in its early stages Nouscom has announced full safety and immunogenicity results from its phase 1b/2 trial of

Drug Safety Research Unit appoints Linda Härmark as its Director The Drug Safety Research Unit has announced Linda Härmark as its new Director. She succeeds Professor Saad Shakir who

Sygnature Discovery has appointed Kieron Hall as Chief Commercial Officer Sygnature Discovery has announced the appointment of Kieron Hall as its new Chief Commercial Officer (CCO) and Board member. Kieron